Notable Runner: 0.89 is United Therapeutics Corp’s (NASDAQ:UTHR) Institutional Investor Sentiment

November 29, 2016 - By Hazel Jackson   ·   0 Comments

Notable Runner: 0.89 is United Therapeutics Corp's (NASDAQ:UTHR) Institutional Investor Sentiment

Sentiment for United Therapeutics Corp (NASDAQ:UTHR)

United Therapeutics Corp (NASDAQ:UTHR) institutional sentiment decreased to 0.89 in Q2 2016. Its down -0.11, from 1 in 2016Q1. The ratio has worsened, as 173 investment managers increased and started new positions, while 173 sold and decreased equity positions in United Therapeutics Corp. The investment managers in our partner’s database now have: 47.41 million shares, down from 49.28 million shares in 2016Q1. Also, the number of investment managers holding United Therapeutics Corp in their top 10 positions decreased from 5 to 4 for a decrease of 1. Sold All: 52 Reduced: 121 Increased: 134 New Position: 39.

United Therapeutics Corporation is a biotechnology company. The company has a market cap of $5.34 billion. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. It has a 8.6 P/E ratio. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 Inhibitor and Monoclonal Antibody (MAb).

About 254,416 shares traded hands. United Therapeutics Corporation (NASDAQ:UTHR) has risen 13.02% since April 26, 2016 and is uptrending. It has outperformed by 7.76% the S&P500.

Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on February, 23. They expect $3.56 EPS, up 61.09% or $1.35 from last year’s $2.21 per share. UTHR’s profit will be $149.00 million for 8.96 P/E if the $3.56 EPS becomes a reality. After $3.63 actual EPS reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts -1.93% negative EPS growth.

According to Zacks Investment Research, “UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.”

Palo Alto Investors Llc holds 13.75% of its portfolio in United Therapeutics Corporation for 1.72 million shares. Krensavage Asset Management Llc owns 275,248 shares or 10.5% of their US portfolio. Moreover, Consonance Capital Management Lp has 6.28% invested in the company for 418,700 shares. The Maryland-based Maryland Capital Management has invested 2.67% in the stock. Amici Capital Llc, a New York-based fund reported 126,451 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 27 insider sales for $5.64 million net activity.

United Therapeutics Corporation (NASDAQ:UTHR) Ratings Coverage

Ratings analysis reveals 33% of United Therapeutics’s analysts are positive. Out of 6 Wall Street analysts rating United Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $95 while the high is $244. The stock’s average target of $174 is 36.37% above today’s ($127.59) share price. UTHR was included in 9 notes of analysts from July 29, 2015. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Buy” rating by Argus Research on Friday, July 31. The stock has “Sector Perform” rating given by RBC Capital Markets on Wednesday, July 29. Argus Research downgraded the stock to “Hold” rating in Tuesday, May 24 report. The firm earned “Outperform” rating on Monday, August 17 by Cowen & Co. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Buy” rating given on Friday, October 28 by Ladenburg Thalmann. As per Friday, April 29, the company rating was downgraded by Ladenburg Thalmann. The rating was downgraded by H.C. Wainwright to “Neutral” on Wednesday, June 15. Barclays Capital maintained it with “Equal-Weight” rating and $145 target price in Friday, February 26 report.

UTHR Company Profile

United Therapeutics Corporation, incorporated on June 26, 1996, is a biotechnology company. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). The Firm is engaged in early-stage research and development into a range of organ transplantation-related technologies. It is also engaged in a range of research and development activities in xenotransplantation, regenerative medicine and ex-vivo lung perfusion, all of which are intended to supply transplantable organs and tissues. These activities are focused on lungs, but are also being applied to other organs, such as hearts and kidneys.

More notable recent United Therapeutics Corporation (NASDAQ:UTHR) news were published by: Fool.com which released: “Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation” on October 14, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United …” published on October 31, 2016, Prnewswire.com published: “United Therapeutics Corporation Announces Executive Leadership Changes” on April 28, 2016. More interesting news about United Therapeutics Corporation (NASDAQ:UTHR) were released by: Prnewswire.com and their article: “United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow …” published on August 10, 2016 as well as Prnewswire.com‘s news article titled: “United Therapeutics Corporation Reports Second Quarter 2016 Financial Results” with publication date: July 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>